CASP3 and leukemia: Stelletin A (56) demonstrated a differential cytotoxicity against human leukemia HL-60 cells (IC50 0.9 μM) compared to human prostate cancer LNCaP cells (IC50 260 μM) by activation of NADPH oxidase, which induces oxidative cell death through a FasL–caspase-3-apoptotic pathway [83].